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ABSTRACT
Objective: To develop a set of health state values based on EuroQol
EQ-5D instrument for the Argentine general population.
Methods: Consecutive subjects attending six primary care centers in
Argentina were selected based on quota sampling and were interviewed
using the EuroQol Group protocol for measurement and valuation of
health studies. Initially, the respondents were randomly assigned a unique
card set; however, to improve efﬁciency, the subjects were later randomly
assigned to one of three ﬁxed sets of EQ-5D states. Using the visual analog
scale (VAS) and time-trade off (TTO) responses for these states, we esti-
mated a valuation model using ordinary least squares regression clustered
by respondent. Predicted values for EQ-5D health states are compared
with published values for the United States.
Results: Six hundred eleven subjects were interviewed by 14 trained inter-
viewers, rendering 6887 TTO and 6892 VAS responses. The model had an
R2 of 0.897 and 0.928 for TTO and VAS, respectively. The mean absolute
difference between observed and predicted values was 0.039 for TTO and
0.020 for VAS, each showing a Lin’s concordance coefﬁcient more than
0.98. Argentine and US TTO-predicted values were highly correlated
(Pearson’s rho = 0.963), although the average absolute difference was
clinically meaningful (0.06), rejecting the US values for nearly two-thirds
of the states (62.8%). The Argentine population placed lower values on
mild states and higher values on severe states.
Conclusion: This study provides an Argentine value set that could be used
locally or regionally, with meaningful and signiﬁcant differences with that
of the United States. Health policy in Latin America must incorporate local
values for sovereignty and validity.
Keywords: cost-effectiveness analysis, HRQOL, patient preference, utility
measurement.
Introduction
The measurement of country-speciﬁc health state values is neces-
sary for evidence-based policymaking. Valuing health states is
analogous to voting over political candidates. Although the
primary purpose of studies like this one is to collect population
values from a representative sample, these responses represent
more than intellectual end points. They are votes for and against
potential health states, and their tallies inform policymakers
which health states the public prefers to others.
In practice, value sets translate health into utilities for use in
economic evaluations. Through their tabulations of cost and
quality of life outcomes, cost-utility analyses are widely used in
developed countries to aid in the decision-making process
between new and existing health technologies and to determine
coverage of health technologies where budget constraints impede
equal access to all alternatives [1–4].
Until this study, Latin American countries had little option
but to base their health policies on value sets taken from devel-
oped countries (e.g., United States, United Kingdom, and Spain).
In response to this paucity, the values set put forth in this article
will better calibrate health policy toward Argentine population
preferences. Our study demonstrates that valuation studies may
be conducted on a smaller scale that is feasible for a developing
country and can better inform country-speciﬁc policies.
More research on the value of health is needed, particularly
in developing countries. Latin America is an increasingly impor-
tant market for drugs and other health technologies. The eight
top Latin American countries represent a market of 468 million
people with a gross domestic product of US$2.7 trillion in
2007, and an expected market value of US$63 billion at retail
prices by 2012 [5]. As the pharmaceuticals market is growing
in Latin America, formal economic evaluations are slowly, but
increasingly, being conducted and applied [6]. However, a
better understanding of these emerging markets requires the
advancement of primary research [7].
In addition to private and governmental institutions, local
values are also important for not-for-proﬁt organizations. To be
culturally competent, ﬁrst-world charities, such as those that
engage in infectious disease control, may wish to acknowledge
and consider local values. This is particularly important in the
cases of health and natural resources, where the decisions directly
affect the lives of the local population. Simply asking the values
of a population grants a degree of local control and demonstrates
respect for autonomy, which is typically in the mission of these
organizations.
The primary aim of this study was to produce a country-
speciﬁc value set for EuroQol 5D instrument (EQ-5D) health
states representing the preferences of the Argentine general popu-
lation. Additionally, Argentine values were then compared with
US values based on statistical and clinical signiﬁcance.
Methods
The EQ-5D descriptive system classiﬁes a health state by combin-
ing a set of scores on ﬁve dimensions: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. The scores on
the dimensions are “1” for the best level and “3” for the worst
level. These scores are used to abbreviate the health states. For
instance, a health state with some problems in walking, with no
problems with self-care, with no problems with performing usual
activities, and with moderate pain and moderate anxiety is abbre-
viated to 21122 [8]. The primary objective of the Measurement
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and Value of Health studies, such as this one, is to collect societal
values for the 243 EQ-5D states to inform country-speciﬁc health
policy decisions.
Because of budget constraints, the sampling frame was the list
of consecutive patients and their accompanying family member
attending six primary care centers: two in Buenos Aires, two in
Rosario City, and two in smaller urban areas. Insufﬁcient funds
were available to apply standard sampling techniques, such as
multistage sampling, which is a limitation of this study. From
these lists, subjects were selected and recruited from October
2003 to July 2004 based on age and sex using a quota system
rendering an initial sample demographically proportional to the
Argentine adult population [9]. Interviews took place at the
primary care centers.
To further reduce study costs, advanced students from medi-
cine and social sciences were recruited and trained for the ﬁeld-
work. Three training workshops for the interviewers were
conducted by two study investigators (AV, VI). Each workshop
lasted 3 hours and included a detailed review of interview tasks
using speciﬁcally designed audiovisual materials: a brief intro-
duction to health preference elicitation methods, speciﬁcally
based on time trade-off (TTO) and visual analog scale (VAS);
TTO and VAS theoretical background and rationale; and
EQ-5D-speciﬁc interviewer’s tasks. Simulated interviews were
held to reduce errors and evaluate interviewers’ skills.
The interview protocol replicated the original Measurement
and Value of Health study conducted in the University of York
and has already been described in detail elsewhere [10–12]. Con-
sented respondents completed an EQ-5D questionnaire describ-
ing their own health using the EQ-5D descriptive system and
the EQ-VAS, a vertical “feeling thermometer” with anchors on
the worst and the best imaginable health states. Afterwards, the
subjects were randomly assigned a set of health states and, with
the assistance of a trained interviewer, completed the ranking
exercise, the VAS exercise, and the TTO exercise developed by
the EuroQol group. The TTO exercise excluded optimal health
and death, which anchor the TTO scale at zero and one, respec-
tively. Lastly, participants completed a personal characteristics
survey, including sociodemographic variables, such as age, sex,
educational status, living conditions, working status, smoking
status, and disease history.
During the ﬁrst portion of the study period (October to
December 2003), the subjects were asked to consider optimal
health, “immediate death,” 22222, and 5 to 10 randomly
assigned states from the UK original set. To improve study efﬁ-
ciency, later respondents were provided one of three ﬁxed set of
states, each of which was composed of mild, moderate, and
severe states based on the New Zealand EQ-5D protocol (e.g.,
group A, B, or C; see Table 1) [13]. Set assignment improved the
efﬁciency of the study design by assuring that each third of the
remaining respondents would evaluate the same states. All three
sets shared a core of seven states, and included eight additional
partially shared or unique states, totaling 15 states valued by
each subject. From the 243 possible EQ-5D health states, the
study included 22 of the 43 states used in the original United
Kingdom protocol as well as “immediate death” and uncon-
scious states.
The TTO responses were measured in 6-month increments,
allowing a range from 1 to -19, and the VAS responses were
measured on a 101-point scale. Dolan [10] replaced the negative
TTO values with (10/x) - 1, where x represents the number of
years spent in the best health state (11111). For consistency and
comparison across measures, all worse than death TTO values
were transformed using Dolan’s transformation; therefore, the
adjusted TTO values ranged from -1 to 1. The VAS responses
were transformed to the common scale by subtracting the VAS
response for “immediate death” and dividing it by the difference
between responses of optimal health and “immediate death.”
The adjusted VAS and TTO values shared anchor points where
one represents optimal health (11111) and zero represents
“immediate death.” For the statistical analysis, the adjusted VAS
and TTO values were linearly transformed by subtracting their
value from one (1-anchored response), so that all predicted
values were positive and represented deviations from optimal
health, where one is the value of “immediate death.”
Statistical analysis included a description of the interview and
respondent characteristics. For the VAS and TTO responses, a
valuation model was estimated using ordinary least squares
(OLS) linear regression with adjusted standard errors for
individual-speciﬁc correlation using the Huber–White method.
Without adjustment, the OLS standard errors misrepresent the
amount of data. By accounting for clustering, the standard errors
are larger, but this change does not affect the coefﬁcient esti-
mates. No individual-speciﬁc intercept shifts (i.e., random or
ﬁxed effects) were included in this analysis for theoretical and
analytical reasons: 1) the scale is anchored at the individual level,
making individual-speciﬁc shifts unnecessary; 2) accounting for
individual-speciﬁc effects is contrary to the objective of societal
valuation, because the resulting predictions would be homo-
genized to a nonrepresentative population by construction; 3)
ﬁxed effects cost one response per subject in terms of degrees of
freedom, which cannot be afforded in this sample; and 4) random
effects require strong parametric assumption, and their inclusion
does not inﬂuence predictions, if symmetric.
The original UK valuation study estimated the “N3” regres-
sion model, which included a constant and 11 variables: two
level indicators for each of the ﬁve dimensions and an indicator
of any 3’s [10]. The N3 model is a restricted form of the “D1”
model used in the US valuation study by Shaw et al. [10,14].
While capturing the same variation as the N3 model, the original
D1 model also included two additional variables: a squared
count of 2’s that is shifted one unit if there were any 2’s (i.e.,
[number of 2’s] ¥ [number of 2’s] + [number of 2’s > 0]) and a
squared count of 3’s (i.e., [number of 3’s] ¥ [number of 3’s]).
Instead of the shifted variable, we include a squared count of 2’s
(i.e., [number of 2’s] ¥ [number of 2’s]) and an indicator of any
2’s (i.e., [number of 2’s > 0]), which is a relaxed form the D1
model that was also proposed in the US valuation study [14].
Table 1 Standardized sets of 15 EQ-5D health states
EQ-5D State
Grouping Set A Set B Set C
Common
to all sets
11111 11111 11111
11112 11112 11112
11121 11121 11121
11211 11211 11211
21111 21111 21111
33333 33333 33333
Immediate death Immediate death Immediate death
Partially
shared
12111 12111
11133 11133
22222 22222
23232 23232
33323 33323
32211 32211
Set-speciﬁc 11122 11131 11113
21232 13311 11312
22233 32313 32223
22323
33321
Unconscious
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In the regression model, the inclusion of a constant, an indi-
cator of any 3’s and an indicator of any 2’s, is equivalent to the
inclusion of the three disjoint category-speciﬁc indicators
included in our 16-variable model: no 3’s; at least one 3, but no
2’s; at least one 3 and at least one 2. In the N3 model, the
coefﬁcients for the latter two indicators are assumed to be equal,
and the coefﬁcients for the count of 2’s when 3’s are present and
the two squared counts are zero. In the D1 model, the difference
between the latter two category-speciﬁc indicators equals the
coefﬁcient for the squared count of 2’s, and the coefﬁcient for the
count of 2’s when 3’s are present is zero. Because the N3 and D1
models are nested within our 16-variable model, we performed
simple Wald tests for linear hypotheses to assess the restrictions
posed by the nested models.
After estimating the 16 regression coefﬁcients, we predict the
values for 242 EQ-5D health states, excluding 11111, of which
only 22 states were directly assessed in the study. These predicted
values represent the Argentine value set. Conﬁdence intervals
(CIs) around the predicted values are estimated by percentile
bootstrap, an empirical technique that does not require paramet-
ric assumption over the full probability distribution [15]. By
resampling respondents with replacement and re-estimating the
16-variable model, we produce a set of 1,000 estimates of each
coefﬁcient and predicted value. Once ranked, the 25th and 975th
estimates describe the 95% CI around the point estimates.
To illustrate similarities and differences in country-speciﬁc
values, the relationship between Argentine and US values was
graphically shown and assessed by linear correlation using Pear-
son’s rho. We further examined the average absolute difference,
the number of states with a clinically meaningful difference
(greater than 0.05), and the statistical signiﬁcance of the differ-
ences in country-speciﬁc predicted values by comparing the 95%
CI of the Argentine predicted values to the predictions from the
United States [14]. All statistical analyses were conducted using
STATA MP 9.2.
Results
Between October 2003 and July 2004, 611 out of 679 subjects
(90%) were successfully recruited to participate in Argentina’s
ﬁrst Measurement and Value of Health study. Through quota
sampling, the sample maintained age, sex, and education status
characteristics that represented the Argentine population (see
Table 2). Fifty-three percent of the respondents were female. The
ages ranged from 18 to 83 years, and the average age was 43.5
years.
Among the 611 respondents, 141 received a nonstandardized
set of EQ-5D health states, 180 received set A, 179 received set
B, and the remaining 111 respondents received set C (see
Table 1). About half of the respondents (47%) were randomly
selected to complete the TTO task ﬁrst and then the VAS exercise
second, while the other 53% completed the valuation tasks in the
reverse order.
The interviews, including the three valuation tasks, took 23
to 120 minutes (average 53 minutes). When the respondents were
asked which task they believed best represents their preferences
over the states, 30% chose the ranking task, 40% chose the VAS
task, 24% chose the TTO task, and 6% did not know or were
not sure. Self-reported accuracy of the tasks was unrelated to the
order of the tasks but signiﬁcantly related to the length of the
interview (chi-square P < 0.05). Respondents whose interviews
took more than an hour were 44% more likely to report that the
ranking task best represented their preference, and 30% were less
likely to choose the TTO task.
The average number of minutes for the rank, VAS, and TTO
tasks were 6.5, 6.1, and 29.4, respectively. Among the respon-
dents, 61% reported difﬁculty with the TTO task, which was
signiﬁcantly greater than the 21.1% and the 12.7% who reported
difﬁculty with rank and VAS tasks, respectively. The respondents
who completed the TTO task ﬁrst reported greater difﬁculty with
the VAS and TTO task (9.7% and 9.3%, respectively) than
respondents who completed the VAS task ﬁrst, which suggested
that task order might inﬂuence respondent perceptions of task
difﬁculty. In summary, the respondents took more time with the
TTO task, had the greatest difﬁculty with its completion, and
reported that it was the least representative of their preferences.
VAS and TTO Response
Adjusted TTO responses were bounded between -1 and 1 by
construction; however, the adjusted VAS values ranged from -3
to 1. Under closer inspection, six adjusted VAS responses were
less than -1, representing the preferences of four respondents.
These four respondents were not removed from the VAS analyti-
cal sample; however, one respondent, who equated “immediate
death” and optimal health, was removed, because his/her
remaining VAS responses could not be rescaled. As a result, only
one respondent was removed on the basis of logical consistency
in VAS responses; however, we retain the respondent’s TTO
values. Two hundred ﬁfty-seven patients (42.6%) had at least one
inconsistency (range 0–7), and only 5% of patients had ﬁve
inconsistencies or more. They were all included in the TTO
analysis.
As in previous studies, responses relating to unconsciousness
were excluded from the analysis, because the state was not part
of the EQ-5D descriptive system. Furthermore, the initial non-
standardized sets included a handful of states that were not
found in the standardized sets (see Table 1), and responses for
these states were excluded from the analysis because of the low
number of observations. While in the standardized set, the
average numbers of response per state was 313 (range 143–609),
in the other states that were excluded from the analysis, the
average number of responses by state was 12 (range 3–26). As a
Table 2 Study sample characteristics and its comparison with Argen-
tine general population data
Sociodemographic variables
Study sample
Argentine
population
n/N % %
Age group (years)
18–39 275/611 45.0 47*
40–59 227/611 37.1 34*
60–79 104/611 17.0 18*
80+ 5/611 0.8 1*
Female 320/611 52.3 52.5*
Educational status
Elementary school uncompleted 73/592 12.3 15*
Elementary school completed 173/592 29.2 29*
High school uncompleted or completed 220/592 37.2 38*
Tertiary level uncompleted or completed 126/592 21.3 18*
Self-reported health status
Excellent 61/609 10 9.2†
Very good 242/609 39.7 25.3†
Good 212/609 34.8 45.5†
Regular 60/609 10 17.3†
Bad 34/609 5.6 2.6†
*National Institute of Statistics and Census, National Census 2001, accessible at http://
www.indec.mecon.ar/webcenso/index.asp
†National Risk Factor Survey, Ministry of Health 2005, accessible at http://www.
msal.gov.ar/htm/Site/enfr/index.asp
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result, the average number of complete responses contributed by
the respondents who received nonstandardized sets were around
seven compared with 12 responses from standardized respon-
dents. The ﬁnal analytical samples included 611 TTO respon-
dents, with a total of 6887 state responses, and 610 VAS
respondents with a total of 6892 responses.
Argentine Values for EQ-5D Health States
The linear regression coefﬁcients and R2 from the VAS and TTO
valuation models are shown in Table 3. Based on the Wald test
results, we rejected the linear constraints imposed by the N3 and
D1 models in favor of the more ﬂexible 16-variable model. In
addition, the coefﬁcient on the count of 2’s when at least one 3 is
present was signiﬁcant and suggested that the detrimental effects
of 2’s lessen when the state contained one or more 3’s.
The level-speciﬁc coefﬁcients were signiﬁcant, and suggested
that the presence of a 2 or 3, instead of a 1, on any domain
lowered health state value. Reduced mobility was associated with
the largest decreases in value and anxiety/depression was associ-
ated with the smallest decreases, except in one case: Unable to
perform usual activities appeared less detrimental than extreme
anxiety and depression in the TTO values.
The category-speciﬁc coefﬁcient for only 1’s and 2’s is not
signiﬁcant in the TTO and VAS models, which demonstrated the
importance of domain and the number of 2’s. The category-
speciﬁc coefﬁcient for only 1’s and 3’s was signiﬁcant and sub-
stantial (>0.35), which suggested the contrary, that the presence
of at least one 3 was more important than which domain had a
3 and the number of 3’s. The category-speciﬁc coefﬁcient for at
least one 2 and one 3 was also signiﬁcant, and differentiated TTO
and VAS values by 0.18 states in this category had lower pre-
dicted TTO values than VAS values. Lastly, the negative coefﬁ-
cients for the squared variables suggested that increasing
the number of 2’s or 3’s had a decreasing detrimental effect on
health state value.
These coefﬁcient estimates allowed for the prediction of the
full set of EQ-5D health state values for the Argentine general
population for both the VAS and TTO models. Figure 1 com-
pared the predicted VAS and TTO values of Argentina. The VAS
values ranged from -0.023 to 0.841, narrower than the TTO
range from -0.3759 to 0.931. Only one state had a signiﬁcantly
negative VAS values, 33333, and 21 states had signiﬁcantly nega-
tive TTO values, possibly due to the 0.18 difference in the
category-speciﬁc indicator. Over the 243 states, the VAS and
TTO values were highly correlated (Pearson’s rho = 0.943).
By comparing the predicted values with the mean responses
for each hypothetical health state, we examined goodness of ﬁt
based on absolute difference for each health state and overall. For
all health states, except 11312, the absolute difference in TTO
value is less than 0.1 and the mean absolute difference was 0.039.
The percentile bootstrap CIs for these differences rejected 0.1 for
18 out of the 22 states, suggesting that most differences are small.
Similar results are found in the VAS values. In terms of agree-
ment, Lin’s coefﬁcient of agreement between the means and the
predicted values is above 0.98 for the TTO and VAS, suggesting
strong concordance. In Table 4, we show both descriptive statis-
tics of the 22 directly elicited states as well as their comparison
with those predicted by the model.
The TTO values of Argentina and the United States were also
highly correlated (Pearson’s rho = 0.963). The average absolute
Table 3 Model estimation
State attribute
Visual analog scale Time trade-off
Coefﬁcient SE P-value Coefﬁcient SE P-value
Mobility, 2 0.248 0.025 0.000 0.189 0.021 0.000
Self-care, 2 0.184 0.026 0.000 0.128 0.022 0.000
Usual activity, 2 0.209 0.024 0.000 0.111 0.020 0.000
Pain/discomfort, 2 0.185 0.024 0.000 0.130 0.018 0.000
Anxiety/depression, 2 0.150 0.022 0.000 0.082 0.015 0.000
Mobility, 3 0.247 0.020 0.000 0.272 0.030 0.000
Self-care, 3 0.178 0.012 0.000 0.209 0.019 0.000
Usual activity, 3 0.148 0.021 0.000 0.067 0.031 0.033
Pain/discomfort, 3 0.157 0.019 0.000 0.209 0.030 0.000
Anxiety/depression, 3 0.116 0.010 0.000 0.135 0.015 0.000
Only 1’s and 2’s 0.028 0.020 0.154 -0.003 0.016 0.857
Only 1’s and 3’s 0.388 0.017 0.000 0.355 0.025 0.000
At least one 2 and at least one 3 0.232 0.031 0.000 0.413 0.042 0.000
Number of 2’s given at least one 3 -0.086 0.010 0.000 -0.117 0.011 0.000
Number of 2’s squared -0.020 0.004 0.000 -0.010 0.003 0.003
Number of 3’s squared -0.008 0.002 0.000 0.005 0.003 0.127
R2 0.928 0.897
Wald test of N3 Model 260.22 0.000 75.25 0.000
Wald test of D1 Model 76.57 0.000 56.08 0.000
SE, standard error.
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Figure 1 Comparison of predicted Argentine visual analog scale (VAS) and
time trade-off (TTO) values.The value scale is anchored at zero by immediate
death and at one by optimal health (11111).
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difference between the two countries’ values was 0.06, and this
difference was greater than 0.05 for more than half of the states
(51.6%). Based on the bootstrap evidence on the 95% CIs of the
Argentine TTO values (see Appendix A), we rejected the US TTO
values for 152 of the 242 states (62.8%), which suggested that
Argentine values differed from US values for nearly two-thirds of
the EQ-5D descriptive system. Figure 2 further shows that the
Argentine population placed lower values on mild states and
higher values on severe health states, leading to greater compres-
sion between state values.
Conclusion
This is the ﬁrst study to provide a population-based value set for
health states in Latin America and the second study in the Western
hemisphere. Although our predictions may not be fully represen-
tative of the entire Argentine adult population because of the
inherent budget and sampling limitations, the sample was com-
posed of both urban and nonurban populations and respected
Argentine sociodemographic characteristics. Additionally, they
had a broadly similar level of self-reported health, which gives
more conﬁdence in the local generalizability of our results. Given
that each country in Latin America is distinctive, it may seem
inappropriate to generalize Argentine values to the rest of Latin
America; however, it also does not seem appropriate to apply the
recently published US weights from the subgroup of 500 Spanish-
speaking Hispanics [16] or the pioneering UK values [10] for
health policy decisions in these developing countries.
In terms of external validity, additional Argentine responses
were not collected to compare the predicted values; however, the
predicted values show strong correlation with those of the US
general population main analysis [14]. Although the choice of the
value set to which to be compared is a matter of judgment, the
absence of other studies in America, the importance of its
Spanish-speaking population, the large sample, and the similarity
of the modeling approach made as choose the US general popu-
lation values and not that of its Spanish-speaking subgroup
analysis as a comparator. Although the sets from both countries
are strongly correlated in rank or after linear adjustment, the
Argentine set exhibits greater compression between health state
values than the US set. This compression suggests that the Argen-
tine population does not value changes in health as much as the
US population; therefore, treatments considered cost-effective in
the United States may not be considered cost-effective in Argen-
tina. Differences between the Argentine and US value sets, which
were signiﬁcant for more than two-thirds of the EQ-5D descrip-
tive system, may be explained by differences in the rescaling of
negative values and the relaxed form of the 16-variable model, as
well as the selection of the sampling frame, differences in lan-
guage, set of states considered, and population preferences. The
exploration and explanation of these differences are an interest-
ing topic for further research. Although national valuations offer
Table 4 Mean adjusted responses and mean absolute difference between predicted values and mean adjusted responses by EQ-5D health state
EQ-5D state
Visual analog scale Time trade-off
Mean
Mean absolute
difference
95% conﬁdence
interval
Mean
Mean absolute
difference
95% conﬁdence
interval
Lower Upper Lower Upper
11112 0.851 0.011 0.005 0.017 0.913 0.018 0.008 0.027
11113 0.526 0.022 0.005 0.041 0.517 0.012 0.001 0.042
11121 0.787 0.020 0.014 0.026 0.887 0.004 0.000 0.012
11122 0.720 0.004 0.000 0.009 0.834 0.003 0.000 0.009
11131 0.459 0.004 0.000 0.015 0.355 0.077 0.061 0.093
11133 0.371 0.002 0.000 0.010 0.311 0.030 0.018 0.045
11211 0.785 0.003 0.000 0.007 0.892 0.009 0.006 0.013
11312 0.627 0.043 0.027 0.059 0.721 0.160 0.139 0.184
12111 0.807 0.000 0.000 0.008 0.886 0.002 0.000 0.010
13311 0.294 0.024 0.014 0.035 0.316 0.032 0.021 0.044
21111 0.749 0.005 0.001 0.009 0.846 0.022 0.016 0.028
21232 0.411 0.039 0.024 0.053 0.345 0.088 0.070 0.107
22222 0.491 0.001 0.000 0.001 0.612 0.000 0.000 0.001
22233 0.374 0.049 0.032 0.065 0.280 0.044 0.024 0.064
22323 0.357 0.000 0.000 0.013 0.333 0.027 0.013 0.039
23232 0.282 0.014 0.004 0.025 0.220 0.011 0.001 0.025
32211 0.381 0.007 0.001 0.014 0.341 0.005 0.000 0.014
32223 0.324 0.026 0.005 0.044 0.315 0.083 0.055 0.108
32313 0.206 0.049 0.034 0.063 0.003 0.063 0.043 0.088
33321 0.265 0.072 0.053 0.092 0.068 0.078 0.051 0.109
33323 0.108 0.029 0.020 0.038 -0.259 0.078 0.065 0.090
33333 -0.015 0.007 0.005 0.009 -0.356 0.020 0.016 0.021
All 0.487 0.020 0.016 0.024 0.453 0.039 0.036 0.044
Lin’s Rho 0.990 0.993 0.990 0.995 0.988 0.985
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Figure 2 Comparison of predicted time trade-off values forArgentina and the
United States.The value scale is anchored at zero by immediate death and at
one by optimal health (11111).
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the beneﬁt of local sovereignty, they also hinder the potential for
transnational comparisons of results from population utility
studies performed in different countries. Nevertheless, they are
more relevant for local decision-making and health economic
evaluations.
With the high response rate, high R2, and low number of
missing responses, internal validity is unlikely to be a signiﬁcant
concern. Based on the Wald test results, the 16-variable model
provided a better ﬁt than both the N3 and the D1 models for
both the VAS and TTO values. In addition, we ﬁnd evidence that
moderate conditions are considered less harmful when coping
with more severe problems and those additional problems are
less detrimental as they accumulate. Further research may
address the relative merits of descriptive capacity and parsimony
in health states valuation studies.
Although TTO and VAS estimations produced correlated pre-
dictions, TTO is generally favored over the VAS, because the
former accounts for time spent in the different health states [17].
Based on the articles presented at the 2007 EuroQol Meeting in
The Hague, The Netherlands, the debate over whether to use the
more psychometric VAS values over the more econometric TTO
values continues within the valuation research community [18].
Although the VAS has potentially interesting properties and is
preferred by respondents, we favor the local and regional eco-
nomic evaluations that continue to apply on choice-based values,
such as the Argentine TTO set.
In summary, this study provides necessary estimates for cost-
utility analyses in Argentina. In addition, we believe that the
results will assist researchers and decision-makers in other parts
of Latin America. Regional researchers concerned with local
validity now have the option of using the recently published US
weights from the subgroup of Spanish-speaking Hispanics [16]
or otherwise the currently presented set. Again, the Argentine
data were collected through quota sampling of subjects from six
primary care centers, and although the sample’s sociodemo-
graphic and self-reported health characteristics reﬂect national
estimates, future work may afford a random sample of the
Argentine population and improve upon the estimates. The evi-
dence suggests that Argentine values are different from US values
and motivates further research in country-speciﬁc health prefer-
ences in developing countries. For reasons of sovereignty and
validity, policymakers should incorporate local preferences into
societal decisions rather than those derived from other countries.
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Appendix A. ArgentineValue Set
EQ-5D State VAS mean 95% CI lower bound 95% CI upper bound TTO mean 95% CI lower bound 95% CI upper bound
11111 1.000 1.000 1.000 1.000 1.000 1.000
11112 0.841 0.830 0.851 0.931 0.921 0.942
11113 0.504 0.476 0.531 0.505 0.468 0.544
11121 0.807 0.798 0.816 0.883 0.873 0.892
11122 0.716 0.695 0.737 0.831 0.822 0.840
11123 0.583 0.545 0.619 0.444 0.390 0.501
11131 0.463 0.453 0.475 0.431 0.411 0.452
11132 0.576 0.552 0.601 0.419 0.386 0.452
11133 0.372 0.359 0.386 0.281 0.264 0.297
11211 0.782 0.774 0.790 0.901 0.895 0.908
11212 0.691 0.672 0.712 0.850 0.834 0.865
11213 0.559 0.524 0.596 0.463 0.410 0.518
11221 0.658 0.633 0.684 0.802 0.784 0.819
11222 0.606 0.580 0.633 0.770 0.754 0.785
11223 0.519 0.490 0.548 0.480 0.437 0.525
11231 0.518 0.494 0.542 0.390 0.356 0.422
11232 0.512 0.494 0.530 0.455 0.434 0.477
11233 0.427 0.401 0.454 0.239 0.204 0.274
11311 0.471 0.450 0.491 0.573 0.545 0.604
11312 0.584 0.565 0.601 0.561 0.540 0.584
11313 0.380 0.363 0.399 0.422 0.397 0.448
11321 0.550 0.531 0.569 0.513 0.488 0.538
11322 0.544 0.524 0.564 0.579 0.558 0.599
11323 0.459 0.441 0.478 0.362 0.338 0.387
11331 0.339 0.306 0.373 0.349 0.297 0.406
11332 0.452 0.425 0.477 0.337 0.297 0.380
11333 0.266 0.242 0.291 0.188 0.148 0.232
12111 0.807 0.796 0.817 0.885 0.875 0.894
12112 0.716 0.692 0.739 0.833 0.813 0.851
12113 0.583 0.546 0.620 0.446 0.388 0.503
12121 0.682 0.656 0.710 0.785 0.763 0.806
12122 0.630 0.601 0.660 0.753 0.733 0.771
12123 0.544 0.513 0.573 0.463 0.416 0.511
12131 0.542 0.514 0.571 0.373 0.335 0.410
12132 0.537 0.514 0.558 0.438 0.413 0.463
12133 0.451 0.424 0.480 0.222 0.184 0.261
12211 0.658 0.629 0.686 0.803 0.777 0.828
12212 0.606 0.575 0.635 0.772 0.746 0.796
12213 0.520 0.489 0.549 0.482 0.435 0.528
12221 0.572 0.539 0.608 0.723 0.696 0.749
12222 0.561 0.538 0.583 0.711 0.695 0.727
12223 0.520 0.488 0.549 0.519 0.475 0.565
12231 0.478 0.454 0.501 0.409 0.382 0.435
12232 0.513 0.491 0.533 0.494 0.471 0.517
12233 0.388 0.366 0.410 0.258 0.231 0.283
12311 0.550 0.529 0.572 0.515 0.488 0.544
12312 0.544 0.524 0.565 0.580 0.559 0.601
12313 0.459 0.440 0.478 0.364 0.337 0.390
12321 0.511 0.487 0.535 0.532 0.508 0.558
12322 0.545 0.518 0.571 0.618 0.587 0.648
12323 0.420 0.401 0.439 0.381 0.360 0.404
12331 0.418 0.385 0.450 0.291 0.246 0.336
12332 0.413 0.380 0.444 0.356 0.314 0.401
12333 0.345 0.318 0.371 0.129 0.091 0.165
13111 0.442 0.413 0.471 0.431 0.386 0.476
13112 0.555 0.512 0.597 0.419 0.349 0.493
13113 0.351 0.318 0.385 0.280 0.229 0.335
13121 0.521 0.480 0.560 0.370 0.305 0.440
13122 0.515 0.479 0.552 0.436 0.379 0.498
13123 0.430 0.387 0.475 0.219 0.146 0.296
13131 0.310 0.292 0.328 0.207 0.181 0.232
13132 0.423 0.390 0.456 0.195 0.143 0.245
13133 0.237 0.213 0.261 0.045 0.016 0.079
13211 0.497 0.459 0.536 0.389 0.325 0.458
13212 0.491 0.458 0.527 0.455 0.398 0.516
13213 0.406 0.361 0.450 0.238 0.165 0.312
13221 0.457 0.425 0.492 0.406 0.354 0.464
13222 0.492 0.454 0.528 0.492 0.437 0.554
13223 0.367 0.331 0.402 0.255 0.196 0.319
13231 0.365 0.333 0.397 0.165 0.117 0.210
13232 0.359 0.335 0.383 0.231 0.191 0.269
13233 0.292 0.253 0.330 0.004 -0.054 0.061
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EQ-5D State VAS mean 95% CI lower bound 95% CI upper bound TTO mean 95% CI lower bound 95% CI upper bound
13311 0.318 0.299 0.335 0.349 0.327 0.370
13312 0.431 0.410 0.452 0.337 0.300 0.377
13313 0.245 0.225 0.264 0.187 0.161 0.213
13321 0.397 0.376 0.419 0.288 0.254 0.326
13322 0.392 0.371 0.412 0.354 0.326 0.387
13323 0.324 0.296 0.350 0.127 0.085 0.173
13331 0.204 0.177 0.229 0.114 0.078 0.151
13332 0.317 0.290 0.342 0.102 0.061 0.142
13333 0.148 0.130 0.164 -0.058 -0.083 -0.033
21111 0.744 0.735 0.752 0.824 0.816 0.831
21112 0.652 0.630 0.676 0.772 0.755 0.788
21113 0.520 0.484 0.557 0.385 0.330 0.440
21121 0.619 0.593 0.647 0.724 0.704 0.743
21122 0.567 0.539 0.597 0.692 0.674 0.708
21123 0.481 0.451 0.509 0.402 0.358 0.447
21131 0.479 0.456 0.504 0.312 0.275 0.346
21132 0.473 0.456 0.492 0.378 0.355 0.399
21133 0.388 0.363 0.415 0.161 0.127 0.197
21211 0.594 0.567 0.623 0.742 0.717 0.765
21212 0.543 0.513 0.573 0.711 0.688 0.733
21213 0.456 0.427 0.484 0.421 0.377 0.466
21221 0.509 0.476 0.544 0.662 0.637 0.687
21222 0.498 0.475 0.520 0.651 0.638 0.664
21223 0.457 0.424 0.487 0.458 0.415 0.502
21231 0.415 0.395 0.436 0.348 0.323 0.371
21232 0.449 0.432 0.466 0.433 0.412 0.454
21233 0.325 0.305 0.343 0.197 0.175 0.219
21311 0.487 0.467 0.507 0.454 0.429 0.479
21312 0.481 0.463 0.499 0.520 0.498 0.539
21313 0.396 0.379 0.414 0.303 0.279 0.329
21321 0.447 0.424 0.471 0.471 0.448 0.496
21322 0.482 0.456 0.507 0.557 0.527 0.590
21323 0.357 0.339 0.376 0.320 0.300 0.341
21331 0.355 0.323 0.387 0.230 0.186 0.275
21332 0.350 0.318 0.381 0.295 0.253 0.340
21333 0.282 0.257 0.305 0.068 0.031 0.104
22111 0.619 0.589 0.648 0.725 0.696 0.751
22112 0.567 0.535 0.599 0.694 0.666 0.719
22113 0.481 0.449 0.509 0.404 0.354 0.451
22121 0.533 0.500 0.570 0.645 0.616 0.672
22122 0.522 0.498 0.545 0.634 0.616 0.651
22123 0.481 0.451 0.509 0.442 0.398 0.488
22131 0.440 0.415 0.463 0.331 0.301 0.358
22132 0.474 0.455 0.492 0.417 0.395 0.438
22133 0.349 0.327 0.371 0.180 0.153 0.206
22211 0.509 0.473 0.546 0.664 0.629 0.696
22212 0.498 0.473 0.521 0.652 0.629 0.673
22213 0.457 0.427 0.485 0.460 0.416 0.503
22221 0.464 0.436 0.491 0.604 0.580 0.627
22222 0.492 0.472 0.510 0.612 0.594 0.632
22223 0.497 0.447 0.542 0.517 0.462 0.577
22231 0.416 0.395 0.435 0.387 0.365 0.408
22232 0.490 0.452 0.525 0.493 0.454 0.531
22233 0.325 0.308 0.342 0.236 0.216 0.256
22311 0.447 0.424 0.472 0.473 0.447 0.497
22312 0.482 0.458 0.505 0.559 0.530 0.585
22313 0.357 0.338 0.375 0.322 0.298 0.343
22321 0.448 0.421 0.474 0.510 0.479 0.541
22322 0.522 0.479 0.565 0.616 0.568 0.665
22323 0.357 0.335 0.379 0.359 0.333 0.387
22331 0.316 0.278 0.352 0.249 0.204 0.298
22332 0.350 0.316 0.381 0.334 0.291 0.384
22333 0.243 0.214 0.270 0.088 0.049 0.124
23111 0.458 0.419 0.497 0.311 0.246 0.380
23112 0.452 0.417 0.488 0.377 0.320 0.437
23113 0.367 0.323 0.411 0.160 0.086 0.237
23121 0.418 0.385 0.452 0.329 0.274 0.387
23122 0.453 0.415 0.489 0.414 0.359 0.477
23123 0.328 0.291 0.365 0.178 0.118 0.242
23131 0.326 0.294 0.357 0.087 0.040 0.134
23132 0.320 0.295 0.345 0.153 0.115 0.190
23133 0.253 0.214 0.290 -0.074 -0.130 -0.016
594 Augustovski et al.
Appendix A. continued
EQ-5D State VAS mean 95% CI lower bound 95% CI upper bound TTO mean 95% CI lower bound 95% CI upper bound
23211 0.394 0.363 0.427 0.347 0.292 0.404
23212 0.428 0.393 0.462 0.433 0.379 0.490
23213 0.303 0.268 0.338 0.196 0.134 0.259
23221 0.394 0.362 0.427 0.384 0.336 0.438
23222 0.469 0.416 0.519 0.490 0.423 0.564
23223 0.304 0.267 0.339 0.234 0.176 0.294
23231 0.262 0.237 0.287 0.123 0.089 0.157
23232 0.297 0.276 0.318 0.209 0.175 0.246
23233 0.189 0.158 0.218 -0.038 -0.083 0.007
23311 0.334 0.313 0.355 0.229 0.195 0.267
23312 0.328 0.310 0.348 0.295 0.266 0.325
23313 0.261 0.234 0.286 0.068 0.025 0.114
23321 0.295 0.272 0.318 0.246 0.220 0.276
23322 0.329 0.305 0.352 0.332 0.300 0.367
23323 0.221 0.199 0.245 0.085 0.050 0.122
23331 0.220 0.191 0.247 -0.005 -0.047 0.035
23332 0.214 0.187 0.240 0.060 0.023 0.095
23333 0.164 0.135 0.193 -0.177 -0.219 -0.135
31111 0.373 0.352 0.393 0.368 0.338 0.399
31112 0.485 0.460 0.509 0.356 0.328 0.387
31113 0.282 0.258 0.307 0.217 0.186 0.249
31121 0.451 0.430 0.472 0.308 0.281 0.337
31122 0.446 0.424 0.469 0.373 0.347 0.402
31123 0.361 0.336 0.386 0.157 0.125 0.191
31131 0.241 0.212 0.270 0.144 0.097 0.194
31132 0.354 0.331 0.379 0.132 0.091 0.172
31133 0.168 0.144 0.191 -0.017 -0.056 0.020
31211 0.427 0.410 0.445 0.326 0.303 0.351
31212 0.422 0.403 0.440 0.392 0.369 0.417
31213 0.337 0.314 0.359 0.175 0.146 0.206
31221 0.388 0.369 0.408 0.344 0.320 0.365
31222 0.422 0.392 0.452 0.429 0.391 0.469
31223 0.297 0.277 0.317 0.193 0.169 0.219
31231 0.296 0.270 0.320 0.102 0.060 0.141
31232 0.290 0.265 0.316 0.168 0.128 0.207
31233 0.222 0.200 0.245 -0.059 -0.093 -0.024
31311 0.249 0.212 0.284 0.286 0.231 0.344
31312 0.362 0.341 0.382 0.274 0.240 0.308
31313 0.176 0.147 0.204 0.125 0.080 0.168
31321 0.328 0.302 0.353 0.226 0.191 0.264
31322 0.322 0.291 0.353 0.291 0.248 0.333
31323 0.255 0.237 0.274 0.064 0.038 0.092
31331 0.135 0.087 0.180 0.051 -0.025 0.135
31332 0.247 0.213 0.282 0.039 -0.019 0.099
31333 0.079 0.049 0.109 -0.120 -0.177 -0.063
32111 0.452 0.432 0.472 0.309 0.283 0.337
32112 0.446 0.424 0.466 0.375 0.352 0.400
32113 0.361 0.337 0.384 0.159 0.126 0.192
32121 0.412 0.392 0.433 0.327 0.303 0.349
32122 0.447 0.417 0.475 0.413 0.376 0.449
32123 0.322 0.302 0.342 0.176 0.151 0.203
32131 0.320 0.295 0.346 0.085 0.044 0.125
32132 0.314 0.288 0.341 0.151 0.112 0.190
32133 0.247 0.223 0.272 -0.076 -0.110 -0.040
32211 0.388 0.371 0.405 0.345 0.326 0.366
32212 0.422 0.396 0.448 0.431 0.398 0.463
32213 0.297 0.280 0.314 0.195 0.171 0.219
32221 0.388 0.361 0.412 0.383 0.350 0.413
32222 0.462 0.412 0.512 0.488 0.430 0.551
32223 0.298 0.274 0.323 0.232 0.198 0.268
32231 0.256 0.227 0.285 0.121 0.079 0.162
32232 0.291 0.261 0.320 0.207 0.160 0.252
32233 0.183 0.160 0.205 -0.040 -0.073 -0.008
32311 0.328 0.305 0.350 0.227 0.194 0.262
32312 0.322 0.294 0.350 0.293 0.252 0.332
32313 0.255 0.239 0.270 0.066 0.041 0.090
32321 0.288 0.254 0.320 0.245 0.203 0.290
32322 0.323 0.286 0.359 0.330 0.277 0.379
32323 0.215 0.191 0.238 0.083 0.052 0.114
32331 0.214 0.174 0.254 -0.007 -0.068 0.056
32332 0.208 0.168 0.250 0.059 -0.005 0.125
32333 0.158 0.133 0.181 -0.179 -0.224 -0.136
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33111 0.220 0.195 0.244 0.143 0.109 0.178
33112 0.332 0.300 0.363 0.131 0.083 0.184
33113 0.146 0.117 0.177 -0.018 -0.057 0.023
33121 0.299 0.272 0.326 0.083 0.040 0.132
33122 0.293 0.266 0.322 0.149 0.108 0.191
33123 0.225 0.189 0.261 -0.078 -0.130 -0.021
33131 0.105 0.080 0.131 -0.091 -0.129 -0.055
33132 0.218 0.190 0.248 -0.103 -0.148 -0.055
33133 0.050 0.029 0.072 -0.263 -0.292 -0.233
33211 0.274 0.250 0.302 0.102 0.059 0.148
33212 0.269 0.245 0.295 0.167 0.129 0.209
33213 0.201 0.167 0.237 -0.060 -0.110 -0.005
33221 0.235 0.213 0.260 0.119 0.085 0.156
33222 0.269 0.237 0.302 0.205 0.158 0.255
33223 0.162 0.133 0.194 -0.042 -0.084 0.006
33231 0.160 0.135 0.188 -0.133 -0.177 -0.089
33232 0.155 0.129 0.180 -0.067 -0.107 -0.027
33233 0.104 0.072 0.135 -0.305 -0.349 -0.259
33311 0.113 0.085 0.140 0.051 0.014 0.088
33312 0.226 0.209 0.246 0.039 0.006 0.073
33313 0.057 0.038 0.077 -0.121 -0.147 -0.097
33321 0.192 0.173 0.212 -0.010 -0.041 0.022
33322 0.187 0.163 0.211 0.056 0.022 0.090
33323 0.136 0.115 0.158 -0.181 -0.213 -0.148
33331 0.016 -0.014 0.046 -0.194 -0.244 -0.141
33332 0.129 0.105 0.154 -0.206 -0.250 -0.164
33333 -0.022 -0.038 -0.009 -0.376 -0.411 -0.342
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